Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Botox for Recurrent Chronic Exertional Compartment Syndrome
NCT05006417Phase 4Terminated
- Sponsor
- University of Wisconsin–Madison
- Start
- Nov 2022
- Primary completion
- Nov 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 4 trial of botulinum toxin type A in Chronic Exertional Compartment Syndrome (CECS), sponsored by University of Wisconsin–Madison. Started Nov 2022; status: terminated.
02
Drugs
botulinum toxin type A
03
Conditions
Chronic Exertional Compartment Syndrome (CECS)
Beyond the preview
Go deeper on NCT05006417.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05006417.